A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2018-06-12
Target enrollment:
Participant gender:
Summary
Phase II study to assess the efficacy of 6 cycles of oral JAK1/2 inhibitor ruxolitinib in
patients with advanced Hodgkin's lymphoma for whom no curative option is available.